Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anakinra in Moderate Asthma Exacerbations
NCT07600190Phase 1Not yet recruiting
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Nov 2026
- Primary completion
- Jan 2029
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised trial of anakinra in asthma (2 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoints: Absolute change in morning Peak Expiratory Flow from baseline at 10 days and Percentage of participants who experience one moderate asthma exacerbation at 6 months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
anakinra
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07600190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07600190.